Overview
A study comparing efficacy of olanzapine versus placebo to prevent nausea and vomiting from moderate emetic risk chemotherapy
Description
A randomized study comparing olanzapine versus placebo in addition to standard antiemetic regimen for preventing nausea and vomiting from moderately emetogenic chemotherapy
Eligibility
Inclusion Criteria:
- histologically confirmed cancer patients who will be started on first dose of oxaliplatin, irinotecan or carboplatin
- age of >18 years old
Exclusion Criteria:
- pregnancy or breast feeding
- has emetic episode within 24 hours
- gut obstruction
- uncontrolled brain metastasis
- allergy to or current use of olanzapine
- concomittant moderate or high emetogenic chemotherapy on day 2-5
- Total bilirubin > 2 mg/dl or creatinine clearance < 30 ml/min
- unable to swallow drug